Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleonora Nicolò

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
JCO Oncology Practice|May 13, 2025
Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug ConjugatesEleonora Nicolò, Caterina Gianni, Paolo Tarantino
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|November 13, 2024
Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?Caterina Gianni, Eleonora Nicolò, Massimo Cristofanilli
Expert Opinion on Therapeutic Targets|November 12, 2021
Novel immune targets for the treatment of triple-negative breast cancerChiara Corti, Eleonora Nicolò, Giuseppe Curigliano
Hematology/Oncology Clinics of North America|November 26, 2022
Biology and Treatment of HER2-Low Breast CancerEleonora Nicolò, Paolo Tarantino, Giuseppe Curigliano
European Journal of Cancer (Oxford, England : 1990)|November 12, 2022
Response to letter entitled: Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer"Paolo Tarantino, Eleonora Nicolò, Giuseppe Curigliano
Current Opinion in Oncology|July 14, 2020
Antibody-drug conjugates in breast cancer: the chemotherapy of the future?Eleonora Nicolò, Paola Zagami, Giuseppe Curigliano
Expert Opinion on Biological Therapy|June 29, 2019
Biosimilars for breast cancerBruna Migliavacca Zucchetti, Eleonora Nicolò, Giuseppe Curigliano
Current Opinion in Oncology|August 25, 2023
HER2-positive breast cancer: cotargeting to overcome treatment resistancePaola Zagami, Luca Boscolo Bielo, Eleonora Nicolò, et al.
Therapeutic Advances in Medical Oncology|February 27, 2023
The HER2-low revolution in breast oncology: steps forward and emerging challengesEleonora Nicolò, Luca Boscolo Bielo, Giuseppe Curigliano, et al.
Cancers|July 2, 2021
Antibody-Drug Conjugates for the Treatment of Breast CancerChiara Corti, Federica Giugliano, Eleonora Nicolò, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
JCO Oncology Practice|May 13, 2025
Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug ConjugatesEleonora Nicolò, Caterina Gianni, Paolo Tarantino
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|November 13, 2024
Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?Caterina Gianni, Eleonora Nicolò, Massimo Cristofanilli
Expert Opinion on Therapeutic Targets|November 12, 2021
Novel immune targets for the treatment of triple-negative breast cancerChiara Corti, Eleonora Nicolò, Giuseppe Curigliano
Hematology/Oncology Clinics of North America|November 26, 2022
Biology and Treatment of HER2-Low Breast CancerEleonora Nicolò, Paolo Tarantino, Giuseppe Curigliano
European Journal of Cancer (Oxford, England : 1990)|November 12, 2022
Response to letter entitled: Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer"Paolo Tarantino, Eleonora Nicolò, Giuseppe Curigliano
Current Opinion in Oncology|July 14, 2020
Antibody-drug conjugates in breast cancer: the chemotherapy of the future?Eleonora Nicolò, Paola Zagami, Giuseppe Curigliano
Expert Opinion on Biological Therapy|June 29, 2019
Biosimilars for breast cancerBruna Migliavacca Zucchetti, Eleonora Nicolò, Giuseppe Curigliano
Current Opinion in Oncology|August 25, 2023
HER2-positive breast cancer: cotargeting to overcome treatment resistancePaola Zagami, Luca Boscolo Bielo, Eleonora Nicolò, et al.
Therapeutic Advances in Medical Oncology|February 27, 2023
The HER2-low revolution in breast oncology: steps forward and emerging challengesEleonora Nicolò, Luca Boscolo Bielo, Giuseppe Curigliano, et al.
Cancers|July 2, 2021
Antibody-Drug Conjugates for the Treatment of Breast CancerChiara Corti, Federica Giugliano, Eleonora Nicolò, et al.
Pageof 5